Lido Advisors
IMNM icon

Lido Advisors’s Immunome IMNM Stock Holding History

Lido Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Sell
48,950
-10,101
-17% -$225K ﹤0.01% 942
2025
Q4 		$691K Hold
59,051
– – ﹤0.01% 1153
2025
Q3 		$691K Sell
59,051
-34
-0.1% -$338 ﹤0.01% 1095
2025
Q2 		$549K Buy
59,085
+6,085
+11% +$49.9K ﹤0.01% 1080
2025
Q1 		$357K Buy
+53,000
New +$508K ﹤0.01% 1142

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Lido Advisors's IMNM Position: Q1 2026 in Review

Lido Advisors reduced its Immunome (IMNM) stake by 17% in Q1 2026, selling an estimated $225K and leaving 48,950 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #942.

Lido Advisors first reported a position in IMNM in Q1 2025 and has held it in 5 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Lido Advisors held 48,950 shares of Immunome worth $1.07M as of Q1 2026.
  • Lido Advisors sold 10,101 Immunome shares in Q1 2026, an estimated $225K.
  • Immunome made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #942 holding.
  • Lido Advisors first reported a position in Immunome in Q1 2025 and has held it in 5 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.